Wong Roger, Gupta Bhaskar, Aylward G William, Laidlaw D Alistair H
Vitreoretinal Service, Guy's and St. Thomas' Hospital NHS Foundation Trust, London.
Retina. 2009 Apr;29(4):492-6. doi: 10.1097/IAE.0b013e31819bab72.
To investigate the effectiveness of a new technique for the identification of occult retinal breaks in vitrectomy retinal detachment repair. Dye Extrusion Technique involves injection of sub retinal dye and extrusion through the unidentified breaks using perfluorocarbon liquid.
Retrospective case note analysis.
rate of break detection, rate of use of local retinopexy, and short-term gas tamponade alone;
anatomical success at 3 months with no long-term tamponade, final visual acuity, progression of proliferative vitreoretinopathy.
Thirty-eight percent of eyes had proliferative vitreoretinopathy of grade C1 or worse. Twenty-five percent underwent primary retinal detachment repair surgery. The remainder underwent repeat operations for previously failed surgery. Breaks were found in 89% of eyes and 81% underwent only local retinopexy and gas tamponade. The overall anatomical success rate was 85% (40/47) which included four cases in which the retina was fully attached awaiting removal of silicone oil. No cases had unexplained loss of vision. No progression of proliferative vitreoretinopathy was noted.
Results suggest that Dye Extrusion Technique may be an effective technique for the identification of occult retinal breaks and may facilitate simple techniques of detachment repair. No evidence of retino-toxicity from the use of trypan blue was found but the study had limited power to detect adverse effects.
探讨一种用于玻璃体切除视网膜脱离修复术中隐匿性视网膜裂孔识别新技术的有效性。染料挤出技术包括视网膜下注射染料,并使用全氟碳液体通过未识别的裂孔挤出。
回顾性病例记录分析。
裂孔检出率、局部视网膜光凝使用率以及单纯短期气体填塞率;
3个月时无需长期填塞的解剖学成功率、最终视力、增殖性玻璃体视网膜病变的进展情况。
38%的患眼患有C1级或更严重的增殖性玻璃体视网膜病变。25%的患者接受了原发性视网膜脱离修复手术。其余患者因先前手术失败而接受再次手术。89%的患眼发现了裂孔,81%的患眼仅接受了局部视网膜光凝和气体填塞。总体解剖学成功率为85%(40/47),其中包括4例视网膜完全附着等待硅油取出的病例。没有病例出现原因不明的视力丧失。未观察到增殖性玻璃体视网膜病变的进展。
结果表明,染料挤出技术可能是一种识别隐匿性视网膜裂孔的有效技术,可能有助于简化视网膜脱离修复技术。未发现使用台盼蓝有视网膜毒性的证据,但该研究检测不良反应的能力有限。